Dose selection for aztreonam-avibactam, including adjustments for renal impairment, for Phase IIa and Phase III evaluation

ConclusionA loading dose plus 3-h maintenance infusions of aztreonam-avibactam in a 3:1 fixed ratio q6h optimizes joint PTA. These analyses supported dose selection for the aztreonam-avibactam Phase III clinical program.Clinical trial registration: NCT01689207; NCT02655419; NCT03329092; NCT03580044.
Source: European Journal of Clinical Pharmacology - Category: Drugs & Pharmacology Source Type: research